Effects of intravenous methylprednisolone therapy on leukocyte and soluble adhesion molecule expression in MS

Neurology

Volumn 50, Issue 1, 1998, Pages 224-229

  Droogan, A G ^a   Crockard, A D ^a   McMillan, S A ^a   Hawkins, S A ^a  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; L SELECTIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; METHYLPREDNISOLONE; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; CELL ADHESION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE ADHERENCE; LEUKOCYTE COUNT; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEROID THERAPY;

EID: 0031907089     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.50.1.224     Document Type: Article

References (42)

1. Milligan NM, Newcombe R, Compston DA. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 1987;50:511-516.
2. Durelli L, Cocito D, Riccio A, et al. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations. Neurology 1986;36:238-243.
3. Long JB, Holaday JW. Blood-brain barrier: endogenous modulation by adrenal-cortical function. Science 1985;227:1580-1582.
4. Stefoski D, Davis FA, Schauf CL. Acute improvement in exacerbating multiple sclerosis produced by intravenous administration of mannitol. Ann Neurol 1985;18:443-450.
5. Abruzzese G, Gandolfo C, Loeb C. "Bolus" methylprednisolone versus ACTH in the treatment of multiple sclerosis. Ital J Neurosci 1983;2:169-172.
6. Barnes MP, Bateman DE, Cleland PG, et al. Intravenous methylprednisolone for multiple sclerosis in relapse. J Neurol Neurosurg Psychiatry 1985;48:157-159.
7. Beck RW, Cleary PA, Trobe JD, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med 1993;329:1764-1769.
8. Baumhueter S, Singer MS, Henzel W, et al. Binding of L-selectin to the vascular sialomucin CD34. Science 1993;262: 436-438.
9. Selmaj K, Brosnan CF, Raine CS. Colocalisation of lymphocytes bearing γδ T-cell receptor and heat shock protein hsp65+ oligodendrocytes in multiple sclerosis. Proc Natl Acad Sci USA 1991;88:6452-6456.
10. Wucherpfennig KW, Newcombe J, Li H, Keddy C, Cuzner ML, Hafler DA. γδ T cell receptor repertoire in acute multiple sclerosis lesions. Proc Natl Acad Sci USA 1992;89:4588-4592.
11. Hvas J, Oksenberg JR, Fernando R, Steinman L, Bernard CC. γδ T cell receptor repertoire in brain lesions of patients with multiple sclerosis. J Neuroimmunol 1993;46:225-234.
12. Chung HT, Samlowski WE, Daynes RA. Modification of the murine immune system by glucocorticosteroids: alterations of the tissue localisation properties of circulating lymphocytes. Cell Immunol 1986;101:571-585.
13. Sackstein R, Borenstein M. The effects of corticosteroids on lymphocyte recirculation in humans: analysis of the mechanism of impaired lymphocyte migration to lymph node following methylprednisolone administration. J Invest Med 1995;43: 68-77.
14. Beer DJ, Center DM. In vitro corticosteroid modulation of lymphocyte migration. Cell Immunol 1980;55:381-383.
15. Abo T, Kawate T, Itoh K, Kumagai K. Studies on the bioperiodicity of the immune response. 1. Circadian rhythms of human T, B, and K cell traffic in the peripheral blood. J Immunol 1981;126:1360-1364.
16. Fisher LE, Ludwig EA, Wald JA, Sloan RR, Middleton E, Jusko WJ. Pharmacokinetics and pharmacodynamics of methylprednisolone when administered at 8 AM versus 4 PM. Clin Pharmacol Ther 1992;51:677-688.
17. Fukuda R, Ichikawa Y, Takaya M, Ogawa Y, Masumoto A. Circadian variations and prednisolone-induced alterations of circulating lymphocyte subsets in man. Int Med 1994;33:733-738.
18. Fauci AS, Dale DC. The effect of hydrocortisone on the kinetics of normal human lymphocytes. Blood 1975;46:235-238.
19. Stuber A, Martin R, Stone LA, Maloni H, McFarland HF. Expression pattern of activation and adhesion molecules on peripheral blood CD4+ T-lymphocytes in relapsing-remitting multiple sclerosis patients: a serial analysis. J Neuroimmunol 1996;66:147-151.
20. Dufour A, Salmaggi A, La Mantia L, Eoli M, Nespolo A, Milanese C. High-dose methylprednisolone treatment-induced changes in immunological parameters in progressive MS patients. Int J Neurosci 1994;75:119-128.
21. Durelli L, Poccardi G, Cavallo R. CD8+ high CD11b+ low T cells (T suppressor-effectors) in multiple sclerosis cerebrospinal fluid are increased during high dose corticosteroid treatment. J Neuroimmunol 1991;31:221-228.
22. Rinehart JJ, Balcerzak SP, Sagone AL, LoBuglio AF. Effects of corticosteroids on human monocyte function. J Clin Invest 1974;54:1337-1340.
23. Hahn BH, MacDermott RP, Jacobs SB, Pletscher LS, Beale MG. Immunosuppressive effects of low doses of glucocorticoids: effects on autologous and allogenic mixed leukocyte reactions. J Immunol 1980;124:2812-2815.
24. MacDermott RP, Stacey MC. Further characterisation of the human autologous mixed leukocyte reaction (MLR). J Immunol 1981;126:729-731.
25. Hartung HP, Michels M, Reiners K, Seeldrayers P, Archelos JJ, Toyka KV. Soluble ICAM-1 serum levels in multiple sclerosis and viral encephalitis. Neurology 1993;43:2331-2335.
26. Jander S, Heidenreich F, Stoll G. Serum and CSF levels of soluble intercellular adhesion molecule-1 (ICAM-1) in inflammatory neurologic diseases. Neurology 1993;43:1809-1813.
27. Dore-Duffy P, Newman W, Balabanov R, et al. Circulating, soluble adhesion proteins in cerebrospinal fluid and serum of patients with multiple sclerosis: correlation with clinical activity. Ann Neurol 1995;37:55-62.
28. Trojano M, Avolio C, Manzari C, et al. Serum and cerebrospinal fluid soluble ICAM-1 levels in clinically active, relapsing-remitting multiple sclerosis: differences according to the presence or absence of MRI gadolinium enhancement [abstract]. Neurology 1996;46:A189.
29. Schleiffenbaum B, Spertini O, Tedder TF, Soluble L-selectin is present in human plasma at high levels and retains functional activity. J Cell Biol 1992;119:229-238.
30. Droogan AG, McMillan SA, Douglas JP, Hawkins SA. Serum and cerebrospinal fluid levels of soluble adhesion molecules in multiple sclerosis: predominant intrathecal release of vascular cell adhesion molecule-1. J Neuroimmunol 1996;64:185-191.
31. Rieckmann P, Altenhofen B, Riegal A, Baudewig J, Felgenhauer K. Soluble adhesion molecules (sVCAM-1 and sICAM-1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis. Ann Neurol 1997;41:326-333.
32. Moreau T, Coles A, Wing M, et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996;119:225-237.
33. Hettmannsperger U, Tenorio S, Orfanos CE, Detmar M. Corticosteroids do not influence TNF- or IL-1 beta-induced ICAM-1 expression of human dermal microvascular endothelial cells in vitro. Arch Dermatol Res 1993;285:347-351.
34. Paleolog EM, Hunt M, Elliott MJ, Feldmann M, Maini RN, Woody JN. Deactivation of vascular endothelium by monoclonal anti-tumour necrosis factor-alpha antibody in rheumatoid arthritis. Arthritis Rheum 1996;39:1082-1091.
35. Kesselring J, Miller DH, MacManus DG, et al. Quantitative magnetic resonance imaging in multiple sclerosis: the effect of high dose intravenous methylprednisolone. J Neurol Neurosurg Psychiatry 1989;52:14-17.
36. Burnham JA, Wright RR, Dreisbach J, Murray RS. The effect of high-dose steroids on MRI gadolinium enhancement in acute denayelinating lesions. Neurology 1991;41:1349-1354.
37. Barkhof F, Frequin ST, Hommes OR, et al. A correlative triad of gadolinium-DTPA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone. Neurology 1992;42:63-67.
38. Miller DH, Thompson AJ, Morrissey SP, et al. High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry 1992;55:450-453.
39. Cronstein BN, Kimmel SC, Levin RI, Martiniuk F, Weissmann G. A mechanism for the anti-inflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelialleukocyte adhesion molecule-1 and intercellular adhesion molecule-1. Proc Natl Acad Sci USA 1992;89:9991-9995.
40. Rosenberg GA, Dencoff JE, Correa N, Reiners M, Ford CC. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology 1996;46:1626-1632.
41. Wielkind U, Walancewicz A, Levine JM, Rohn MC. Type II glucocorticoid receptors are expressed in oligodendrocytes and astrocytes. J Neurosci Res 1990;27:360-373.
42. Defer GL, Barre J, Ledudal P, Tillement JP, Degos JD. Methylprednisolone infusion during acute exacerbation of MS: plasma and CSF concentrations. Eur Neurol 1995;35:143-148.